Owlstone Medical Stock
Diagnostics company developing a breathalyzer for disease
Sign up today and learn more about Owlstone Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Owlstone Medical Stock
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®.
Owlstone Medical’s world-leading Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, U.K. with support through our office in Research Triangle Park, NC, USA, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.
Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the development of Tests and RUO Panels for the early detection of disease with an emphasis on cancer, and on precision medicine initially targeting liver and respiratory disease.
The Breath Biopsy OMNI (Owlstone Medical Novel Insights) Assay is Owlstone Medical’s comprehensive solution for end-to-end breath sample collection and VOC analysis, which is being deployed with large pharma including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline, and leading academic institutions. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.
Investors
Ventura Capital
Foxconn Technology Group
Medtekwiz Advisory Ltd
Horizons Ventures
Impossible Foods, Eat Just, Scopely, Improbable, Airwallex, Hippo Insurance, Divergent 3D, Blockstream, States Title, HZO
Aviva Ventures
Funding History
March 2016 | $7.0M |
---|---|
December 2016 | $11.5M |
March 2018 | $15.0M |
January 2019 | $9.3M |
May 2019 | $10.4M |
September 2021 | $58.0M |
Management
Co-Founder & Chief Executive Officer
Billy Boyle
Co-Founder & Chief Operating Officer
David Ruiz Alonso
Chief Financial Officer
Martin Cartwright
Press
dlvr - Jun, 16 2023
Owlstone Medical delivers breath biopsy test datadlvr - Mar, 17 2023
Owlstone Medical collaborates with Bicycle Therapeuticsnews-medical - Dec, 10 2022
Owlstone Medical Presents Breath Biopsy® VOC Atlasbiospace - Jan, 24 2022
SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medicalfiercebiotech - Sep, 9 2021
Breath biopsy company Owlstone Medical hoovers up $58M funding round